- Home
- EPM vs CRDF Comparison
EPM vs CRDF Comparison
Compare EPM & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EPM
- CRDF
- Stock Information
- Founded
- EPM 2003
- CRDF 1999
- Country
- EPM United States
- CRDF United States
- Employees
- EPM N/A
- CRDF N/A
- Industry
- EPM Oil & Gas Production
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EPM Energy
- CRDF Health Care
- Exchange
- EPM Nasdaq
- CRDF Nasdaq
- Market Cap
- EPM 154.4M
- CRDF 152.3M
- IPO Year
- EPM 1996
- CRDF N/A
- Fundamental
- Price
- EPM $3.76
- CRDF $1.99
- Analyst Decision
- EPM Hold
- CRDF Strong Buy
- Analyst Count
- EPM 1
- CRDF 4
- Target Price
- EPM $4.50
- CRDF $10.63
- AVG Volume (30 Days)
- EPM 361.2K
- CRDF 726.1K
- Earning Date
- EPM 11-11-2025
- CRDF 11-06-2025
- Dividend Yield
- EPM 12.44%
- CRDF N/A
- EPS Growth
- EPM N/A
- CRDF N/A
- EPS
- EPM N/A
- CRDF N/A
- Revenue
- EPM $85,232,000.00
- CRDF $501,000.00
- Revenue This Year
- EPM N/A
- CRDF N/A
- Revenue Next Year
- EPM $1.13
- CRDF N/A
- P/E Ratio
- EPM N/A
- CRDF N/A
- Revenue Growth
- EPM N/A
- CRDF N/A
- 52 Week Low
- EPM $3.86
- CRDF $1.90
- 52 Week High
- EPM $6.14
- CRDF $5.64
- Technical
- Relative Strength Index (RSI)
- EPM 20.69
- CRDF 34.85
- Support Level
- EPM $4.35
- CRDF $1.96
- Resistance Level
- EPM $4.60
- CRDF $2.33
- Average True Range (ATR)
- EPM 0.13
- CRDF 0.11
- MACD
- EPM -0.05
- CRDF -0.03
- Stochastic Oscillator
- EPM 5.06
- CRDF 3.85
About EPM Evolution Petroleum Corporation Inc.
Evolution Petroleum Corp is an independent energy company focused on owning and investing in onshore oil and natural gas properties across the United States. Its portfolio includes non-operated interests in various production fields such as CO2 enhanced oil recovery in Louisiana, secondary recovery production in Wyoming, and shale gas reservoirs in Texas and North Dakota. The company generates revenue from the production and sale of oil and natural gas, leveraging specialized technologies to extend reservoir life and enhance recoveries.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.